Ariad Pharmaceuticals Inc fka ARIA

[biomaven0]

Restructuring the Merck deal, which had been something of a fiasco and retaining all rights to Ponatinib as it continues to move along and become fully derisked. Jerk or not, he's had a good run over the past few years.

Well yes and no. The Merck deal should never have been structured the way it was to begin with - to think Ariad could play along with a big pharma on equal terms in a major oncology development program was hubris. But Harvey did negotiate a good exit.

And instead of spending the money on fighting Lilly on that stupid patent suit, I suspect we could have had '113 in the clinic six months ago.

But he has done an excellent job on the finance side and on resisting the obvious temptation to partner pona too early. So let's call it an A- overall.

Peter